FrancophonIA/ELRC3.0 huggingface dataset:
English: Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with deferasirox 10 - 30 mg/kg/day (dispersible tablet formulation) for 1 year may also reduce levels of iron in the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).
Slovenian: Omejeni klinični podatki (29 bolnikov z normalnim delovanjem srca ob izhodišču), pridobljeni z magnetnoresonančnim slikanjem (MRI), kažejo, da zdravljenje z deferasiroksom v odmerku 10-30 mg/kg/dan (v obliki disperzibilnih tablet) v obdobju 1 leta lahko zniža tudi koncentracije železa v srcu (v povprečju se je MRI T2* podaljšal z 18,3 na 23,0 milisekunde).
English: If no satisfactory control is achieved at doses above 21 mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible.
Slovenian: Če bolnik pri zdravljenju z odmerki nad 21 mg/kg ni zadovoljivo urejen, ne sme vztrajati pri zdravljenju s takimi odmerki, ampak je treba, kadar je le mogoče, pretehtati možnosti drugih načinov zdravljenja.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.
Slovenian: Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti ali kancerogenega potenciala ne kažejo posebnega tveganja za človeka.
English: In a retrospective meta-analysis of 2,102 adult and paediatric beta-thalassaemia patients with transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four open label studies of up to five years' duration, a mean creatinine clearance decrease of 13.2% in adult patients (95% CI: −14.4% to −12.1%; n=935) and 9.9% (95% CI: −11.1% to −8.6%; n=1,142) in paediatric patients was observed during the first year of treatment.
Slovenian: V retrospektivni metaanalizi podatkov 2.102 odraslih in pediatričnih bolnikov z beta talasemijo in s preobremenitvijo z železom zaradi transfuzij krvi, ki so jih zdravili z deferasiroksom v obliki disperzibilnih tablet v okviru dveh randomiziranih kliničnih študij in štirih odprtih študij s trajanjem zdravljenja do pet let, so v prvem letu zdravljenja pri odraslih bolnikih opažali znižanje povprečne vrednosti očistka kreatinina za 13,2 % (95 % IZ: -14,4 % do -12,1 %; n=935), pri pediatričnih bolnikih pa za 9,9 % (95 % IZ: -11,1 % do -8,6 %; n=1.142).
English: The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication (see section 4.4).
Slovenian: Večina teh bolnikov je imela okvaro ledvic, renalno tubulopatijo (Fanconijev sindrom), diarejo ali stanja, pri katerih je nastanek kislinsko-baznega neravnovesja znan zaplet (glejte poglavje 4.4).
English: • Kidney stones
Slovenian: • ledvični kamni
English: The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral bisphosphonates may increase the risk of gastrointestinal toxicity (see section 4.4).
Slovenian: Sočasna uporaba deferasiroksa z zdravilnimi učinkovinami, za katere je znano, da lahko povzročajo ulkuse, na primer z nesteroidnimi protivnetnimi zdravili (vključno z visokimi odmerki acetilsalicilne kisline), s kortikosteroidi ali s peroralnimi difosfonati, lahko poveča tveganje za gastrointestinalno toksičnost (glejte poglavje 4.4).
English: Approximate tablet dimensions 12.8 mm × 6.00 mm.
Slovenian: Približna velikost tablete je 12,8 mm x 6,00 mm.
English: Therefore, the concomitant use of deferasirox with theophylline is not recommended.
Slovenian: Iz tega razloga sočasna uporaba deferasiroksa in teofilina ni priporočena.
English: Hypersensitivity reactions (including anaphylactic reactions and angioedema) Metabolism and nutrition disorders Not known:
Slovenian: preobčutljivostne reakcije (med drugim anafilaktične reakcije in angioedem) Presnovne in prehranske motnje neznana pogostnost:
English: If only very poor haemosiderosis control is achieved at doses up to 21 mg/kg, a further increase (to a maximum of 28 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered.
Slovenian: Če je bolnik s hemosiderozo zelo slabo urejen ob zdravljenju z odmerki do 21 mg/kg, morda tudi z nadaljnjim zviševanjem odmerka (do največ 28 mg/kg) ne bo prišlo do zadovoljive urejenosti in bo treba pretehtati možnosti drugih načinov zdravljenja.
English: Most reports of hepatic failure involved patients with significant morbidities including pre-existing liver cirrhosis.
Slovenian: V večini poročil o odpovedi jeter je šlo za bolnike s pomembnimi boleznimi, med drugim z že prej prisotno cirozo jeter.
English: What you need to know before you take Deferasirox Mylan
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Deferasiroks Mylan
English: The main findings were kidney toxicity and lens opacity (cataracts).
Slovenian: Ugotovili so predvsem toksičnost za ledvice in motnost leče (katarakto).
English: Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life- threatening or fatal, have been reported.
Slovenian: Poročali so hudih kožnih neželenih reakcijah (SCAR - severe cutaneous adverse reactions), med drugim o Stevens-Johnsonovem sindromu (SJS), toksični epidermalni nekrolizi (TEN) in reakciji na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - drug reaction with eosinophilia and systemic symptoms), ki so lahko življenjsko nevarni oziroma smrtni.
English: Clinical efficacy studies were conducted with deferasirox dispersible tablets.
Slovenian: Klinične študije za vrednotenje učinkovitosti so bile izvedene z deferasiroksom v obliki disperzibilnih tablet.
English: • 14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,
Slovenian: • 14 mg na kilogram telesne mase za odrasle bolnike, ki ne prejemajo rednih transfuzij krvi,
English: In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.4).
Slovenian: V dveh kliničnih študijah rast in spolno dozorevanje pediatričnih bolnikov, zdravljenih z deferasiroksom do 5 let, nista bila motena (glejte poglavje 4.4).
English: No inhibition of deferasirox metabolism by hydroxyurea was observed in vitro.
Slovenian: In vitro niso opazili nobene inhibicije metabolizma deferasiroksa zaradi hidroksiuree.
English: Mylan S.A.S Tél : +33 4 37 25 75 00
Slovenian: Mylan S.A.S Tel: +33 4 37 25 75 00
English: Cases of acute renal failure have been reported following post-marketing use of deferasirox (see section 4.8).
Slovenian: Na podlagi uporabe deferasiroksa v obdobju trženja so poročali o primerih akutne ledvične odpovedi (glejte poglavje 4.8).
English: The single dose Cmax was not affected, but an increase of theophylline Cmax is expected to occur with chronic dosing.
Slovenian: Uporaba enkratnega odmerka ni vplivala na najvišjo koncentracijo Cmax, pri kroničnem odmerjanju pa je mogoče pričakovati zviševanje najvišje koncentracije Cmax teofilina.
English: The maximum recommended daily dose for Deferasirox Mylan film-coated tablets is:
Slovenian: • Največji priporočeni dnevni odmerek zdravila Deferasiroks Mylan v obliki filmsko obloženih tablet je:
English: An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.
Slovenian: Interakcij med deferasiroksom in drugimi substrati CYP2C8, kot je paklitaksel, ni mogoče izključiti.
English: In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 µg/l), dose reductions in steps of 3.5 to 7 mg/kg should be considered to maintain serum ferritin levels within the target range and to minimise the risk of overchelation.
Slovenian: Pri bolnikih, pri katerih je koncentracija feritina dosegla ciljno vrednost (običajno med 500 in 1.000 µg/l), je treba razmisliti o postopnem zniževanju odmerka v korakih po 3,5 do 7 mg/kg, da bi koncentracijo feritina v serumu lahko obdržali v okviru ciljnih vrednosti in čim bolj zmanjšali tveganje za prekomerno kelacijo.
English: Clear transparent PVC/PVDC/Aluminium blisters containing 30 or 90 film-coated tablets and unit dose blisters of 30 × 1 tablets.
Slovenian: Prozorni transparentni PVC/PVDC/aluminijski pretisni omoti, ki vsebujejo 30 ali 90 filmsko obloženih tablet in enoodmerni pretisni omoti, ki vsebujejo 30 x 1 tableto.
English: Starting dose
Slovenian: Začetni odmerek
English: What Deferasirox Mylan is and what it is used for
Slovenian: Kaj je zdravilo Deferasiroks Mylan in za kaj ga uporabljamo
English: Other information
Slovenian: Drugi podatki
English: Approximate tablet dimensions 10.00 mm × 4.5 mm.
Slovenian: Približna velikost tablete je 10,0 mm x 4,5 mm.
English: Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during Deferasirox Mylan therapy and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse reaction is suspected.
Slovenian: Zdravniki in bolniki morajo biti ves čas zdravljenja z zdravilom Deferasiroks Mylan pozorni na znake in simptome ulceracij in krvavitev gastrointestinalnega trakta, v primeru suma na resen gastrointestinalni neželeni učinek pa nemudoma začeti z dodatnimi pregledi in zdravljenjem.
English: In paediatric patients with non-transfusion-dependent thalassaemia syndromes, dosing should not exceed 7 mg/kg.
Slovenian: Pri pediatričnih bolnikih s katerim od sindromov talasemije, neodvisnih od transfuzij, odmerek ne sme preseči 7 mg/kg.
English: Deferasirox Mylan is available in clear, transparent PVC/PVdC /aluminium blister packs containing 30 or 90 film-coated tablets, in unit dose blister pack of 30 tablets and in white, plastic bottles with white opaque screw cap with aluminium seal containing 90 and 300 tablets.
Slovenian: Zdravilo Deferasiroks Mylan je na voljo v prozornih, transparentnih PVC/PVdC /aluminijskih pretisnih omotih, ki vsebujejo po 30 ali 90 filmsko obloženih tablet, v enoodmernemu pretisnemu omotu po 30 tablet in v belih, plastičnih plastenkah z belim netransparentnim zamaškom z aluminijasto zaporko, ki vsebujejo po 90 in 300 tablet.
English: If any SCAR is suspected, Deferasirox Mylan should be discontinued immediately and should not be reintroduced.
Slovenian: V primeru suma na katerokoli hudo kožno reakcijo je treba zdravilo Deferasiroks Mylan bolniku takoj ukiniti, ponovno pa se mu ga ne sme več predpisati.
English: Deferasirox promotes excretion of iron, primarily in the faeces.
Slovenian: Deferasiroks pospešuje izločanje železa iz organizma, prvenstveno z blatom.
English: For deferasirox film-coated tablets, a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox film-coated tablets that is numerically one third of the deferoxamine dose).
Slovenian: Za odmerjanje deferasiroksa v obliki filmsko obloženih tablet je mogoče uporabiti razmerje odmerkov 3:1 (to je odmerek deferasiroksa v obliki filmsko obloženih tablet, ki je številčno enak eni tretjini odmerka deferoksamina).
English: The food should be immediately and completely consumed.
Slovenian: Bolnik naj odmerek zaužije takoj in v celoti.
English: If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).
Slovenian: Če je uporaba kombinacije teh dveh zdravil nujna, je treba bolnika skrbno klinično spremljati in mu meriti koncentracijo glukoze v krvi (glejte poglavje 4.4).
English: They should be monitored closely by their doctor for side effects that may require a dose adjustment.
Slovenian: Zdravnik mora starejše bolnike bolj skrbno spremljati glede neželenih učinkov, zaradi katerih bi bilo morda treba prilagoditi odmerek.
English: Deferasirox Mylan is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).
Slovenian: Uporaba zdravila Deferasiroks Mylan ni priporočena pri bolnikih s hudo okvaro jeter (Child-Pugh stopnje C).
English: Caution should be exercised in patients who are taking Deferasirox Mylan in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm³ (50 × 10
Slovenian: Previdnost je potrebna pri bolnikih, ki jemljejo zdravilo Deferasiroks Mylan v kombinaciji z zdravilnimi učinkovinami, za katere je znano, da lahko povzročajo ulkuse, kot so nesteroidna protivnetna zdravila, kortikosteroidi ali peroralni difosfonati, pri bolnikih, ki prejemajo antikoagulante, in pri bolnikih s koncentracijo trombocitov, ki je nižja od 50.000/mm
English: In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), and Deferasirox Mylan must be used with caution in such patients.
Slovenian: Pri bolnikih z zmerno okvaro jeter (Child-Pugh stopnje B) je treba odmerek znatno znižati in nato postopno zviševati do meje 50 % (glejte poglavji 4.4 in 5.2).
English: For patients who are unable to swallow whole tablets, Deferasirox Mylan film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple).
Slovenian: Za bolnike, ki ne morejo pogoltniti celih tablet, je mogoče filmsko obložene tablete Deferasiroks Mylan zdrobiti in celoten odmerek primešati mehki hrani, na primer jogurtu ali jabolčni kaši.
English: However, in patients with liver iron concentration <7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
Slovenian: Pri bolnikih s koncentracijo železa v jetrih <7 mg Fe/g suhe teže, zdravljenih bodisi z deferasiroksom v obliki disperzibilnih tablet (5 in 10 mg/kg) ali deferoksaminom (20 do 35 mg/kg) pa neinferiornost ni bila ugotovljena zaradi neuravnoteženega odmerjanja obeh kelatorjev.
English: Abnormal serum creatinine and creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively.
Slovenian: O nenormalni koncentraciji kreatinina v serumu so poročali pri 5,5 % bolnikov, o nenormalni vrednosti očistka kreatinina pa pri 1,8 % bolnikov.
English: In addition, in patients with liver iron concentration ≥7 mg Fe/g dw with various rare anaemias or sickle cell disease, deferasirox dispersible tablets up to 20 and 30 mg/kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta-thalassaemia.
Slovenian: Poleg tega je pri bolnikih s koncentracijo železa v jetrih ≥7 mg Fe/g suhe teže in z različnimi redkimi vrstami anemije ali s srpastocelično anemijo deferasiroks v obliki disperzibilnih tablet v odmerkih do 20 in 30 mg/kg povzročil primerljivo znižanje koncentracije železa v jetrih in feritina v serumu v primerjavi z bolniki z beta talasemijo.
English: Increase 3.5 - 7 mg/kg/day
Slovenian: zviševanje 3,5 - 7 mg/kg/dan
English: In a clinical study using single doses of 20 mg/kg deferasirox dispersible tablets, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child-Pugh Class A) and by 76% in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to subjects with normal hepatic function.
Slovenian: V klinični študiji z enkratnimi odmerki deferasiroksa 20 mg/kg v obliki disperzibilnih tablet je bila pri bolnikih z blago okvaro jeter (Child-Pugh stopnje A) povprečna izpostavljenost za 16 % večja kot pri bolnikih z normalnim delovanjem jeter, pri bolnikih z zmerno okvaro jeter (Child-Pugh stopnje B) pa je bila večja za 76 %.
English: Treatment with Deferasirox Mylan should be initiated and maintained by physicians experienced in the treatment of chronic iron overload.
Slovenian: Zdravljenje z zdravilom Deferasiroks Mylan naj uvede in nadaljuje zdravnik z izkušnjami pri zdravljenju kronične preobremenitve z železom.
English: There have been post-marketing reports of metabolic acidosis.
Slovenian: V obdobju trženja zdravila so poročali o pojavu metabolne acidoze.
English: Interaction with repaglinide and other agents metabolised by CYP2C8
Slovenian: Medsebojno delovanje z repaglinidom in drugimi zdravili, katerih presnova poteka s CYP2C8
English: Very common (may affect more than 1 in 10 people)
Slovenian: Zelo pogosti (lahko se pojavijo pri več kot 1 od 10 bolnikov)
English: Interaction with midazolam and other agents metabolised by CYP3A4
Slovenian: Medsebojno delovanje z midazolamom in drugimi zdravili, katerih presnova poteka s CYP3A4
English: Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 µg/l).
Slovenian: Terapijo s kelacijo železa je primerno uvesti samo v primeru dokazane preobremenitve z železom (pri koncentraciji železa v jetrih ≥5 mg Fe/g suhe teže oziroma pri koncentraciji feritina v serumu ves čas >800 µg/l).
English: After every 3 to 6 months of treatment, a dose increase in increments of 3.5 to 7 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well.
Slovenian: Po vsakih 3 do 6 mesecih zdravljenja je treba razmisliti o zvišanju odmerka v korakih po 3,5 do 7 mg/kg, če je pri bolniku koncentracija železa v jetrih ≥7 mg Fe/g suhe teže oziroma ima koncentracijo feritina v serumu ves čas >2.000 µg/l in ta ne kaže trenda zniževanja, bolnik pa zdravilo dobro prenaša.
English: Cardiac function should be monitored in patients with severe iron overload during long-term treatment with Deferasirox Mylan.
Slovenian: Pri bolnikih s hudo preobremenitvijo z železom je treba med dolgotrajnim zdravljenjem z zdravilom Deferasiroks Mylan spremljati delovanje srca.
English: [Bottles]
Slovenian: [Pretisni omoti]
English: • Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).
Slovenian: v primeru glikozurije pri tistih, ki nimajo sladkorne bolezni, in v primeru nizkih koncentracij kalija, fosfatov, magnezija ali uratov v serumu, fosfaturije in aminoacidurije (s spremljanjem po potrebi).
English: For patients who are unable to swallow whole tablets, the film-coated tablets may be crushed and administered by sprinkling the full dose onto soft food, e.g. yogurt or apple sauce (pureed apple).
Slovenian: Za bolnike, ki ne morejo pogoltniti celih tablet, je mogoče filmsko obložene tablete zdrobiti in celoten odmerek primešati mehki hrani, na primer jogurtu ali jabolčni kaši.
English: Monthly monitoring of serum ferritin is recommended in order to assess the patient's response to therapy and to avoid over-chelation (see section 4.2).
Slovenian: Priporočeno je mesečno spremljanje vrednosti feritina v serumu zaradi presoje bolnikovega odziva na zdravljenje in za preprečevanje prekomerne kelacije (glejte poglavje 4.2).
English: The average Cmax of deferasirox in subjects with mild or moderate hepatic impairment was increased by 22%.
Slovenian: Pri bolnikih z blago ali zmerno okvaro jeter je bila povprečna Cmax deferasiroksa višja za 22 %.
English: Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated with Deferasirox Mylan.
Slovenian: O renalni tubulopatiji so poročali večinoma pri otrocih in mladostnikih, ki so imeli beta talasemijo in so prejemali zdravilo Deferasiroks Mylan.
English: • The need for annual auditory and ophthalmic testing
Slovenian: • potreba po letnem testiranju sluha in vida;
English: On average, serum ferritin decreased by 222.0 µg/l in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 115 µg/l in patients treated with placebo (p<0.001).
Slovenian: Koncentracija feritina se je v povprečju znižala za 222,0 µg/l pri bolnikih, ki so prejemali deferasiroks v obliki disperzibilnih tablet (z začetnim odmerkom 10 mg/kg/dan) in se zvišala za 115 µg/l pri bolnikih, ki so prejemali placebo (p<0,001).
English: In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered.
Slovenian: Pri bolnikih, ki niso ustrezno urejeni ob zdravljenju z odmerkom 21 mg/kg (pri katerih na primer koncentracija feritina v serumu vztraja nad 2.500 µg/l in ne kaže trenda zniževanja s časom), je mogoče razmisliti o uporabi odmerkov do 28 mg/kg.
English: Deferasirox Mylan can be used by people aged 65 years and over at the same dose as for other adults.
Slovenian: Ljudje, ki so stari 65 let ali več, lahko uporabljajo zdravilo Deferasiroks Mylan v enakih odmerkih kot odrasli.
English: Deferasirox Mylan is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).
Slovenian: Uporaba zdravila Deferasiroks Mylan ni priporočena pri bolnikih s hudo okvaro jeter (Child-Pugh stopnje C) (glejte poglavje 5.2).
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznak Uporabno do in EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: There have been post-marketing reports of metabolic acidosis occurring during treatment with deferasirox.
Slovenian: V obdobju trženja zdravila so poročali o pojavu metabolne acidoze med zdravljenjem z deferasiroksom.
English: The recommended initial daily dose of Deferasirox Mylan film-coated tablets is 14 mg/kg body weight.
Slovenian: Priporočeni začetni dnevni odmerek zdravila Deferasiroks Mylan v obliki filmsko obloženih tablet je 14 mg/kg telesne mase.
English: Transfusional iron overload:
Slovenian: Preobremenitev z železom zaradi transfuzij:
English: [Unit dose blisters] 30 × 1 film-coated tablets
Slovenian: [Enoodmerni pretisni omoti] 30 x 1 filmsko obložena tableta
English: In these patients, closer monitoring of LIC and serum ferritin is essential to avoid over-chelation (see section 4.4).
Slovenian: Pri teh bolnikih je nujno natančno spremljati koncentracijo železa v jetrih in feritina v serumu, da ne pride do prekomerne kelacije (glejte poglavje 4.4).
English: (acquired Fanconi syndrome), glycosuria
Slovenian: (pridobljeni Fanconijev sindrom),
English: Once a satisfactory body iron level has been achieved (LIC <3 mg Fe/g dw or serum ferritin <300 µg/l), treatment should be stopped.
Slovenian: Ko bolnik doseže zadovoljivo raven železa v telesu (koncentracijo železa v jetrih <3 mg Fe/g suhe teže ali koncentracijo feritina v serumu <300 µg/l), je treba zdravljenje zaključiti.
English: Deferasirox Mylan is not recommended for children aged under 2 years.
Slovenian: Uporaba zdravila Deferasiroks Mylan pri otrocih, mlajših od 2 leti, ni priporočljiva.
English: When serum creatinine is elevated and if another abnormality has been detected (e.g. proteinuria, signs of Fanconi syndrome).
Slovenian: • kadar je koncentracija kreatinina v serumu zvišana in se ugotovi še druga nepravilnost (kot je proteinurija, znaki Fanconijevega sindroma);
English: In an iron-balance metabolic study in iron-overloaded adult thalassaemic patients, deferasirox at daily doses of 10, 20 and 40 mg/kg (dispersible tablet formulation) induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.
Slovenian: V presnovni študiji ravnovesja železa je pri odraslih bolnikih s talasemijo in preobremenitvijo z železom deferasiroks v dnevnem odmerku 10, 20 in 40 mg/kg (v obliki disperzibilnih tablet) povzročil povprečno neto ekskrecijo 0,119; 0,329 oziroma 0,445 mg Fe/kg telesne mase/dan.